|
| 35139274 | Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. | N Engl J Med | 2022 |
| 35101364 | Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial. | J Geriatr Oncol | 2022 |
| 34301749 | Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. | Clin Cancer Res | 2021 |
| 33721561 | 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. | Lancet Oncol | 2021 |
| 32278621 | Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. | Ann Oncol | 2020 |
| 32083990 | Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. | J Clin Oncol | 2020 |
| 29472587 | Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer. | Pharmacogenomics J | 2019 |
| 28929359 | Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. | Breast Cancer Res Treat | 2018 |
| 29893791 | Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial. | Ann Oncol | 2018 |
| 29435853 | Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial. | Breast Cancer Res Treat | 2018 |
| 29656866 | Corrigendum to "An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint<sup>®</sup>)" [Eur J Cancer 75 (April 2017) 5-13]. | Eur J Cancer | 2018 |
| 29433963 | Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. | Lancet Oncol | 2018 |
| 29092024 | Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. | Ann Oncol | 2018 |
| 28027521 | Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer. | Eur J Cancer | 2017 |
| 28088074 | Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives. | Cancer Treat Rev | 2017 |
| 28084333 | Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. | Mod Pathol | 2017 |
| 28477490 | Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial. | Eur J Cancer | 2017 |
| 28214658 | An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint<sup>®</sup>). | Eur J Cancer | 2017 |
| 28292559 | Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. | Eur J Cancer | 2017 |
| 28324265 | Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study. | Breast Cancer Res Treat | 2017 |
| 29027483 | CDK4/6 blockade in breast cancer: current experience and future perspectives. | Expert Opin Investig Drugs | 2017 |
| 29122511 | From bench to clinical trials the EORTC experience in biology-based clinical cancer research. | J Egypt Natl Canc Inst | 2017 |
| 28690677 | The past and future of breast cancer treatment-from the papyrus to individualised treatment approaches. | Ecancermedicalscience | 2017 |
| 26724641 | A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378). | Eur J Cancer | 2016 |
| 27741402 | Targeted adjuvant therapy in breast cancer. | Expert Rev Anticancer Ther | 2016 |
| 27643748 | Endocrine treatment in breast cancer: Cure, resistance and beyond. | Cancer Treat Rev | 2016 |
| 27396647 | Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials. | Lancet Oncol | 2016 |
| 27563654 | The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. | Ann Transl Med | 2016 |
| 27557300 | 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. | N Engl J Med | 2016 |
| 27289552 | Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial. | Eur J Cancer | 2016 |
| 25668732 | Management of locally advanced breast cancer-perspectives and future directions. | Nat Rev Clin Oncol | 2015 |
| 25869460 | Corrigendum: Management of locally advanced breast cancer--perspectives and future directions. | Nat Rev Clin Oncol | 2015 |
| 25917256 | The need for post-mastectomy radiotherapy in patients with IBC. | Nat Rev Clin Oncol | 2015 |
| 26025767 | Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study. | Eur J Cancer | 2015 |
| 24958324 | Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer. | Clin Breast Cancer | 2014 |
| 25315501 | Small breast cancers: when and how to treat. | Cancer Treat Rev | 2014 |
| 24091128 | A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer. | Breast | 2013 |
| 22000696 | A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer. | Clin Lung Cancer | 2012 |
| 22669571 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. | Cancer Chemother Pharmacol | 2012 |
| 22349809 | A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. | Cancer Chemother Pharmacol | 2012 |
| 22425915 | ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. | J Thorac Oncol | 2012 |
| 21157449 | Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. | Br J Cancer | 2011 |
| 21254862 | Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. | Expert Opin Pharmacother | 2011 |